Manila Times Business
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trialsNamely, ~67% of patients treated with SLK achieved HiSCR75 at the one-year mark, with more than one quarter of patients achieving inflammatory remission (IH
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Korea Deep Learning Secures Back-to-Back Global AI Benchmark Wins Over Big Tech
3h ago
Murj® Expands Global Footprint with Commercial Launch in Australia and New Zealand
4h ago
3D AI Studio Launches Flow: Node-Based 3D Workflows That Run in the Browser With No GPU or Setup
4h ago
7 killed and dozens injured following series of weekend shootings in Chicago
6h ago